Review of therapeutically equivalent alternatives to short acting β2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers

Thorax

Volumn 54, Issue 12, 1999, Pages 1087-1092

  Hughes, D A ^a   Woodcock, A ^b   Walley, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

CFC free; Chlorofluorocarbons (CFCs); Hydrofluorocarbons; Inhaled bronchodilators; Metered dose inhalers; Salbutamol; Terbutaline; Therapeutic equivalence

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; PROPELLANT; SALBUTAMOL; TERBUTALINE;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; HUMAN; INTERMETHOD COMPARISON; MEDICAL INFORMATION; META ANALYSIS; METERED DOSE INHALER; POWDER INHALER; PRIORITY JOURNAL;

EID: 0032701090     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.12.1087     Document Type: Article

References (61)

1. D'Souza S. The Montreal protocol and essential use exemptions. J Aerosol Med 1995;8(Suppl 1):13-7.
2. European Commission. European Community Strategy for the Phaseout of CFCs in Metered Dose Inhalers. A communication from the European Commission prepared jointly by DG XI and DG III.
3. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clinical implications of differences in effectiveness. Clin Immunother 1996;6:273-99.
4. British Thoracic Society, et al. The British guidelines on asthma management: 1995 Review and position statement. Thorax 1997;52(Suppl 1):S1-21.
5. Cross D, Nelson HS. The role of the peak flow meter in the diagnosis and management of asthma. J Allergy Clin Immunol 1991;87:120-8.
6. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: The importance of rigorous methods. BMJ 1996;313:36-9.
7. Zanen P, Lammers J-WJ. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995;48:179-84.
8. Dockhorn R, Vanden Burgt JA, Ekholm BP, et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995;96:50-6.
9. Desager KN, Van Bever HP, Vermeire PA. Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler. Lancet 1996;348:200-1.
10. Ruffin R, Mitchell C, Thompson P, et al. A placebo controlled comparison of the dose-response effects of salbutamol sulphate in chlorofluorocarbon (CFC) vs hydrofluoroal kane (HFA-134a) propellants in asthmatics. Am J Respir Crit Care Med 1995;151:A58.
11. Kleerup EC, Tashkin DP, Cline AC, et al. Cumulative doseresponse study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109:702-7.
12. Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics. Chest 1998;113:283-9.
13. 3M Health Care. Four Week Safety and Efficacy Study of Airomir™ Inhaler and CFC-salbutamol Inhaler in Children with Asthma. Data on File 1141-SILV, 3M Health Care.
14. Grady J, Stahl E, Davis S, et al. A comparison of albuterol MDI in CFC propellant (P11/12), albuterol MDI in non-CFC propellant (HFA134a), and placebo (HFA134a propellant alone) in asthmatic subjects. Am J Respir Crit Care Med 1996;153:A62.
15. Taggart SCO, Custovic A, Richards DH, et al. GR106642X: A new, non-ozone depleting propellant for inhalers. BMJ 1995;310:1639-40.
16. Custovic A, Taggart SCO, Stuart A, et al. Efficacy of a new non-ozone depleting formulation for salbutamol. J Pharm Med 1995;5:161-8.
17. Baumgarten C, Kettner J, Sykes AP. Efficacy and safety of salbutamol 100 mcg prn via a pressurised inhaler formulated with GR106642X. Am J Respir Crit Care Med 1995;151:A57.
18. Duncan D, Paterson IC, Harris D, et al. Comparison of the bronchodilator effects of salbutamol inhaled as a dry powder and by conventional pressurised aerosol. Br J Clin Pharmacol 1977;4:669-71.
19. Hartley JPR, Nogrady SG, Gibby OM, et al. Bronchodilator effects of dry salbutamol powder administered by Rotahaler. Br J Clin Pharmacol 1977;4:673-5.
20. Latimer KM, Roberts R, Dolovich J, et al. Salbutamol: Comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects. Can Med Assoc J 1982;127: 857-9.
21. Tukiainen H, Terho EO. Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level. Eur J Clin Pharmacol 1985;27:645-7.
22. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, et al. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990;45:469-73.
23. Bronsky EA, Spector SL, Pearlman DS, et al. Albuterol aerosol versus albuterol Rotacaps® in exercise-induced bronchospasm in children. J Asthma 1995;32:207-14.
24. Hetzel MR, Clark TJH. Comparison of salbutamol Rotahaler with conventional pressurized aerosol. Clin Allergy 1977;7:563-8.
25. Svedmyr N, Löfdahl C-G, Svedmyr K. The effect of powder aerosol compared to pressurized aerosol. Eur J Respir Dis Suppl 1982;63:81-8.
26. Kemp JP, Furukawa CT, Bronsky EA, et al. Albuterol treatment for children with asthma: A comparison of inhaled powder and aerosol. J Allergy Clin Immunol 1989;83:697-702.
27. Raimondi AC, Schottlender J, Lombardi D, et al. Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Chest 1997;112:24-8.
28. Hartley JPR, Nogrady SG, Seaton A. Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. Br J Dis Chest 1979;73:271-6.
29. Croner S, Hedenskog S, Kjellman N-I, et al. Salbutamol by powder or spray inhalation in childhood asthma. Allergy 1980;35:589-92.
30. Pover GM, Langdon CG, Jones SR, et al. Evaluation of a breath operated powder inhaler. J Int Med Res 1988;16:201-3.
31. Mathieu M, Goldman M, Lellouche N, et al. Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDI) and a "diskhaler". Eur J Clin Pharmacol 1992;42:435-8.
32. Hindle M, Newton DAG, Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. Chest 1995;107:629-33.
33. Allen & Hanburys. Clinical Efficacy and Safety of the Accuhaler Compared with the Pressurised Metered-dose Inhaler (MDI) for the Delivery of a Single Dose of Ventolin (Salbutamol) 200 Micrograms in Adult Asthmatics. Data on file SALB3001, Allen & Hanburys.
34. Green R, Clay M, Woodcock A. The Accuhaler™/Diskus™ inhaler for delivering salbutamol during bronchoconstriction. Am J Respir Crit Care Med 1996;153:A61.
35. Evans Medical. Influence of Inspiratory Flow Rate on the Bronchodilator Response to Salbutamol Delivered via Clickhaler™ (A Dry Powder Inhaler) or a Metered Dose Inhaler in Patients with Asthma. Data on file COBRA, Evans Medical: 1997.
36. O'Callaghan C, Everard ML, Russell RIR, et al. Efficacy and safety of salbutamol delivered by a novel multidose dry powder inhaler (DPI) and a pressurized metered dose inhaler (MDI) in paediatric asthma. Eur Respir J 1997;16:126s.
37. Morice AH, Peake MD, Allen MB, et al. Evaluation of a novel salbutamol dry powder inhaler: Clinical equivalence to a standard metered dose inhaler and in-use stability. Br J Clin Pharmacol 1996;42:658P.
38. Villiger B, Schwarz F. Comparison of inhaled terbutaline either via MDI or via a new DPI Turbuhaler®. Eur Respir J 1990;3:94s.
39. Ruffin RE, Thompson PI, Mitchell CA, et al. Terbutaline via Turbuhaler™ and pMDI: A study of the relative dose response in patients with asthma. Am J Respir Crit Care Med 1997;155:A672.
40. Jackson L, Ståhl E, Holgate ST. Terbutaline via pressurised metered dose inhaled (P-MDI) and Turbuhaler® in highly reactive asthmatic patients. Eur Respir J 1994;7:1598-601.
41. Borgström L, Derom E, Ståhl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636-40.
42. Rufin P, Benoist MR, De Blic J, et al. Terbutaline powder in asthma exacerbations. Arch Dis Child 1991;66:1465-7.
43. Svenonius E, Arborelius M, Wiberg R, et al. A comparison of terbutaline inhaled by Turbuhaler® and by chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma. Allergy 1994;49:408-12.
44. Hirsch T, Peter-Kern M, Koch R, et al. Influence of inspiratory capacity on bronchodilation via Turbuhaler® or pressurized metered-dose inhaler in asthmatic children: A comparison. Respir Med 1997;91:341-6.
45. Herer B. Comparison of the bronchodilator effect of terbutaline inhaled from a spacer and from Turbuhaler in asthmatic adults. Eur Respir J 1993;6:593s.
46. Mortensen J, Groth S, Lange P, et al. Effect of terbutaline on mucociliary clearance in asthmatic and healthy subjects after inhalation from a pressurised inhaler and a dry powder inhaler. Thorax 1991;46:817-23.
47. Formgren H, Sjökvist A, Ståhl E, et al. Terbutaline in COPD comparison between Turbuhaler® and chlorofluorocarbon (CFC) inhaler. Lung 1994;172:271-80.
48. Selroos O, Löfroos A-B, Pietinalho A, et al. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 1994;49:1228-30.
49. Tønnesen F, Laursen LC, Evald T, et al. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994;105:697-700.
50. Persson G, Gruvstad E, Ståhl E. A new multiple dose powder inhaler (Turbuhalerœ) compared with a pressurized inhaler in a study of terbutaline in asthmatics. Eur Respir J 1988;1:681-1.
51. Johnsen CR, Rung Weeke E. Turbuhaler® a new device for dry powder terbutaline inhalation. Allergy 1988;43:392-5.
52. Ekström T, Andersson AC, Skedinger M, et al. Dose potency relationship of terbutaline inhaled via Turbuhaler or via a pressurized metered dose inhaler. Ann Allergy Astha Immunol 1995;74:328-32.
53. Fuglsang G, Pedersen S. Comparison of a new multidose powder inhaler with a pressurised aerosol in children with asthma. Pediatr Pulmonol 1989;7:112 5.
54. Laberge S, Spier S, Drblik SP, et al. Comparison of inhaled terbutaline administered by either the Turbuhaler dry powder inhaler or a metered-dose inhaler with spacer in preschool children with asthma. J Pediatr 1994;124:815-7.
55. Huhquist C, Ahlström H, Kjellman N-IM, et al. A double-blind comparison between a new multi-dose powder inhaler (Turbuhaler®) and metered dose inhaler in children with asthma. Allergy 1989;44:167-70.
56. Osterman K, Norborg A-M, Ståhl E. A multiple dose powder inhaler (Turbuhaler®) compared with conventional aerosol. Allergy 1989;44:294-7.
57. Osterman K, Ståhl E, Kallén A. Bricanyl Turbuhaler in the treatment of asthma: A six week multi-centre study carried out in Sweden, the United Kingdom, Denmark, Norway and Finland. Eur Respir J 1991;4:175-9.
58. Ahlström H, Svenonius E, Svensson M. Treatment of asthma in pre-school children with inhalation of terbutaline in Turbuhaler compared with Nebuhaler. Allergy 1989;44: 515-8.
59. Replacement of Chloroflourocarbons (CFC) in Metered Dose Inhalation Products. London: MCA, document CPMP/III/5378/93:233-42.
60. Wung BJO, Hargreave FE. Bioequivalence of metered-dose inhaled medications. J Allergy Clin Immunol 1993;92:373-9.
61. British National Formulary. No. 36, British Medical Association and Royal Pharmaceutical Society of Great Britain, London: September 1998.